HRP20210299T1 - Inhibitori histonske demetilaze - Google Patents
Inhibitori histonske demetilaze Download PDFInfo
- Publication number
- HRP20210299T1 HRP20210299T1 HRP20210299TT HRP20210299T HRP20210299T1 HR P20210299 T1 HRP20210299 T1 HR P20210299T1 HR P20210299T T HRP20210299T T HR P20210299TT HR P20210299 T HRP20210299 T HR P20210299T HR P20210299 T1 HRP20210299 T1 HR P20210299T1
- Authority
- HR
- Croatia
- Prior art keywords
- optionally substituted
- aryl
- alkyl
- heteroaryl
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462017201P | 2014-06-25 | 2014-06-25 | |
| PCT/US2015/037812 WO2015200709A1 (en) | 2014-06-25 | 2015-06-25 | Histone demethylase inhibitors |
| EP15811523.8A EP3160952B1 (en) | 2014-06-25 | 2015-06-25 | Histone demethylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210299T1 true HRP20210299T1 (hr) | 2021-04-16 |
Family
ID=54929774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210299TT HRP20210299T1 (hr) | 2014-06-25 | 2015-06-25 | Inhibitori histonske demetilaze |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US10385047B2 (enExample) |
| EP (3) | EP3741749A1 (enExample) |
| JP (1) | JP6521535B2 (enExample) |
| KR (1) | KR102591897B1 (enExample) |
| CN (2) | CN111909083B (enExample) |
| AR (1) | AR100997A1 (enExample) |
| AU (1) | AU2015279719B2 (enExample) |
| BR (1) | BR112016030367A2 (enExample) |
| CA (1) | CA2953437C (enExample) |
| CL (1) | CL2016003301A1 (enExample) |
| CO (1) | CO2017000359A2 (enExample) |
| CY (1) | CY1123906T1 (enExample) |
| DK (1) | DK3160952T3 (enExample) |
| EA (1) | EA031200B1 (enExample) |
| EC (1) | ECSP17004931A (enExample) |
| ES (1) | ES2862648T3 (enExample) |
| HR (1) | HRP20210299T1 (enExample) |
| HU (1) | HUE053876T2 (enExample) |
| IL (1) | IL249629A0 (enExample) |
| LT (1) | LT3160952T (enExample) |
| MX (1) | MX375219B (enExample) |
| NZ (1) | NZ728120A (enExample) |
| PL (1) | PL3160952T3 (enExample) |
| PT (1) | PT3160952T (enExample) |
| SA (1) | SA516380585B1 (enExample) |
| SG (1) | SG11201610813TA (enExample) |
| SI (1) | SI3160952T1 (enExample) |
| TW (2) | TWI758004B (enExample) |
| WO (1) | WO2015200709A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150100814A (ko) | 2012-12-21 | 2015-09-02 | 콴티셀 파마슈티컬스, 인크. | 히스톤 데메틸라제 억제제 |
| NZ728120A (en) | 2014-06-25 | 2023-06-30 | Celgene Quanticel Res Inc | Histone demethylase inhibitors |
| KR20170048591A (ko) | 2014-09-17 | 2017-05-08 | 셀젠 콴티셀 리서치, 인크. | 히스톤 데메틸라제 억제제 |
| US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN108698997A (zh) | 2015-12-28 | 2018-10-23 | 赛尔基因昆蒂赛尔研究公司 | 组蛋白脱甲基酶抑制剂 |
| JP6970681B2 (ja) * | 2016-03-15 | 2021-11-24 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| JP7442439B2 (ja) * | 2017-03-30 | 2024-03-04 | アルベルト－ルートヴィヒ－ユニバーシティー フライブルク | Ｋｄｍ４阻害剤 |
| CN109825551B (zh) * | 2019-02-21 | 2022-08-02 | 深圳大学 | 一种评价组蛋白赖氨酸去甲基转移酶活性的方法 |
| CN111679072B (zh) * | 2020-06-15 | 2022-04-29 | 温州医科大学 | Kdm6b蛋白在乳腺癌预后评估试剂盒、诊断试剂盒中的应用 |
| US20250025451A1 (en) * | 2021-04-09 | 2025-01-23 | Celgene Corporation | Treatment of cancer with kdm4 inhibitors |
| AU2022331536A1 (en) * | 2021-08-18 | 2024-02-22 | Celgene Corporation | Process for preparing histone demethylase inhibitors |
| US20250134874A1 (en) * | 2021-12-23 | 2025-05-01 | Tachyon Therapeutics, Inc. | Pharmaceutical formulations comprising 3-({[(4r)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro-2h-1-benzopyran-4-yl]methyl}amino)pyridine-4-carboxylic acid |
| WO2023240253A2 (en) | 2022-06-10 | 2023-12-14 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| IL317852A (en) * | 2022-06-23 | 2025-02-01 | Cleveland Clinic Found | 3-βHSD1 inhibitors and compositions and uses thereof |
| CA3268325A1 (en) * | 2022-09-21 | 2024-03-28 | Celgene Corporation | CRYSTALLINE FORMS OF L-LYSINE SALT OF 3-({[(4R)-7-{METHYL[4-(PROPAN-2-YL)PHENYL]AMINO}-3,4-DIHYDRO-2H-1-BENZOPYRAN-4-YL]METHYL}AMINO)PYRIDINE-4-CARBOXYLIC ACID AS A HISTONE DEMETHYLASE INHIBITOR |
| CN115974647B (zh) * | 2022-12-05 | 2024-09-03 | 江苏宏邦化工科技有限公司 | 以四氢-4-甲基-2-苯基-2h-吡喃-4-醇为原料制备苯乐戊醇的方法 |
| WO2025085527A1 (en) * | 2023-10-16 | 2025-04-24 | The Cleveland Clinic Foundation | 3βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3795044B2 (ja) * | 2001-09-14 | 2006-07-12 | メシルジーン、インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| DE102004039876A1 (de) | 2004-06-23 | 2006-01-26 | Lanxess Deutschland Gmbh | Herstellung von fluorierten 1,3-Benzodioxanen |
| TW200808793A (en) | 2006-03-07 | 2008-02-16 | Smithkline Beecham Corp | Prolyl hydroxylase inhibitors |
| WO2007118137A1 (en) * | 2006-04-07 | 2007-10-18 | Methylgene Inc. | Benzamide derivatives as inhibitors of histone deacetylase |
| US7898712B2 (en) | 2008-06-27 | 2011-03-01 | Lockheed Martin Corporation | Risley integrated steering module |
| GB201112607D0 (en) | 2011-07-22 | 2011-09-07 | Glaxo Group Ltd | Novel compounds |
| EP2701699B1 (en) | 2011-04-28 | 2019-10-16 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| WO2013143597A1 (en) * | 2012-03-29 | 2013-10-03 | Glaxo Group Limited | Demethylase enzymes inhibitors |
| US20140162266A1 (en) | 2012-12-05 | 2014-06-12 | Bio-Rad Laboratories, Inc. | Methods for polymerase chain reaction copy number variation assays |
| US8987461B2 (en) * | 2012-12-06 | 2015-03-24 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| HUE037312T2 (hu) * | 2012-12-19 | 2018-08-28 | Celgene Quanticel Res Inc | Hiszton demetiláz inhibitorok |
| KR20150100814A (ko) * | 2012-12-21 | 2015-09-02 | 콴티셀 파마슈티컬스, 인크. | 히스톤 데메틸라제 억제제 |
| NZ728120A (en) | 2014-06-25 | 2023-06-30 | Celgene Quanticel Res Inc | Histone demethylase inhibitors |
| JP7442439B2 (ja) * | 2017-03-30 | 2024-03-04 | アルベルト－ルートヴィヒ－ユニバーシティー フライブルク | Ｋｄｍ４阻害剤 |
-
2015
- 2015-06-25 NZ NZ728120A patent/NZ728120A/en unknown
- 2015-06-25 HR HRP20210299TT patent/HRP20210299T1/hr unknown
- 2015-06-25 TW TW109143458A patent/TWI758004B/zh active
- 2015-06-25 SG SG11201610813TA patent/SG11201610813TA/en unknown
- 2015-06-25 SI SI201531524T patent/SI3160952T1/sl unknown
- 2015-06-25 AU AU2015279719A patent/AU2015279719B2/en active Active
- 2015-06-25 DK DK15811523.8T patent/DK3160952T3/da active
- 2015-06-25 EP EP20184106.1A patent/EP3741749A1/en active Pending
- 2015-06-25 PL PL15811523T patent/PL3160952T3/pl unknown
- 2015-06-25 US US15/321,702 patent/US10385047B2/en active Active
- 2015-06-25 EP EP20184107.9A patent/EP3738960A1/en not_active Withdrawn
- 2015-06-25 EP EP15811523.8A patent/EP3160952B1/en active Active
- 2015-06-25 JP JP2016574454A patent/JP6521535B2/ja active Active
- 2015-06-25 WO PCT/US2015/037812 patent/WO2015200709A1/en not_active Ceased
- 2015-06-25 CN CN202010813617.0A patent/CN111909083B/zh active Active
- 2015-06-25 EA EA201692483A patent/EA031200B1/ru unknown
- 2015-06-25 KR KR1020177002223A patent/KR102591897B1/ko active Active
- 2015-06-25 HU HUE15811523A patent/HUE053876T2/hu unknown
- 2015-06-25 US US14/751,007 patent/US9242968B2/en active Active
- 2015-06-25 CA CA2953437A patent/CA2953437C/en active Active
- 2015-06-25 ES ES15811523T patent/ES2862648T3/es active Active
- 2015-06-25 PT PT158115238T patent/PT3160952T/pt unknown
- 2015-06-25 TW TW104120633A patent/TWI715533B/zh active
- 2015-06-25 BR BR112016030367A patent/BR112016030367A2/pt not_active Application Discontinuation
- 2015-06-25 LT LTEP15811523.8T patent/LT3160952T/lt unknown
- 2015-06-25 CN CN201580045921.2A patent/CN106660982B/zh active Active
- 2015-06-25 AR ARP150102042A patent/AR100997A1/es not_active Application Discontinuation
- 2015-06-25 MX MX2016017407A patent/MX375219B/es active IP Right Grant
- 2015-12-09 US US14/963,754 patent/US9447046B2/en active Active
-
2016
- 2016-07-26 US US15/220,118 patent/US9586902B2/en active Active
- 2016-12-18 IL IL249629A patent/IL249629A0/en unknown
- 2016-12-22 CL CL2016003301A patent/CL2016003301A1/es unknown
- 2016-12-22 SA SA516380585A patent/SA516380585B1/ar unknown
-
2017
- 2017-01-09 US US15/402,100 patent/US9815828B2/en active Active
- 2017-01-16 CO CONC2017/0000359A patent/CO2017000359A2/es unknown
- 2017-01-24 EC ECIEPI20174931A patent/ECSP17004931A/es unknown
- 2017-10-24 US US15/792,570 patent/US9994561B2/en active Active
-
2018
- 2018-05-04 US US15/971,749 patent/US10106534B2/en active Active
-
2021
- 2021-03-01 CY CY20211100169T patent/CY1123906T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210299T1 (hr) | Inhibitori histonske demetilaze | |
| SA518400660B1 (ar) | مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2 | |
| PH12018501179A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| MX2020005622A (es) | Compuestos de indol sustituidos con arilo y heteroarilo. | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2016011992A (es) | Derivados de piperidina-diona. | |
| EA201650031A1 (ru) | Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1 | |
| EA201791692A1 (ru) | 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ | |
| EA201990019A1 (ru) | Соединения и композиции для подавления активности shp2 | |
| BR112016029846A2 (pt) | ?composto, composição farmacêutica, métodos para o método para tratamento de um humano, para inibição da atividade de um polipeptídio de fosfatidilinositol 3-quinase e inibição excessiva ou reações imunes destrutivas ou crescimento ou uma proliferação de células de câncer, kit, e, uso de um composto, um sal farmaceuticamente aceitável, isômero, ou uma mistura do mesmo? | |
| NZ726723A (en) | Heteroaryl compounds for kinase inhibition | |
| MX2018000512A (es) | Compuestos de indazaol y azaindazol como inhibidores de la cinasa 4 asociada al receptor de interlucina 1 (irak-4). | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| MX386089B (es) | Compuesto heterociclico utilizado como inhibidor de fgfr. | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| EA201890165A1 (ru) | Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа | |
| HUE070489T2 (hu) | Lanifibranor deuterizált származékainak terápiás alkalmazása | |
| MX369369B (es) | Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
| NZ629037A (en) | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same | |
| JP2017523152A5 (enExample) | ||
| EA201401082A1 (ru) | Фармацевтические препараты, содержащие антагонисты ccr3 |